Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AAIC 2022 | Early predictive value of plasma biomarkers for amyloid positivity

Charlotte Teunissen, PhD, Amsterdam University Medical Centers, Amsterdam, Netherlands shares recent findings from the Netherlands Twin Registry that demonstrate the predictive value of plasma biomarkers for amyloid positivity in people as early as aged 58. Blood samples obtained 10 years prior to cerebrospinal fluid (CSF)/PET amyloid analysis showed there were differences in baseline amyloid beta, GFAP and phospho-tau levels between individuals who went on to test amyloid-positive and amyloid-negative at the 10-year follow-up. Longitudinal increases in phospho-tau and GFAP were also seen in those that went on to test amyloid-positive. Additionally, GFAP levels at the time of CSF/PET analysis were significantly related to decline in cognition in the 2-4 years that followed. This interview took place at the Alzheimer’s Association International Conference (AAIC) 2022 in San Diego, CA.


Research of CET is supported by the European Commission (Marie Curie International Training Network, grant agreement No 860197 (MIRIADE), Innovative Medicines Initiatives 3TR (Horizon 2020, grant no 831434) EPND ( IMI 2 Joint Undertaking (JU) under grant agreement No. 101034344grant no) and JPND (bPRIDE), National MS Society (Progressive MS alliance) and Health Holland, the Dutch Research Council (ZonMW), Alzheimer Drug Discovery Foundation, The Selfridges Group Foundation, Alzheimer Netherlands, Alzheimer Association. CT is recipient of ABOARD, which is a public-private partnership receiving funding from ZonMW (#73305095007) and Health~Holland, Topsector Life Sciences & Health (PPP-allowance; #LSHM20106). ABOARD also receives funding from Edwin Bouw Fonds and Gieskes-Strijbisfonds.
CET has a collaboration contract with ADx Neurosciences, Quanterix and Eli Lilly, performed contract research or received grants from AC-Immune, Axon Neurosciences, Bioconnect, Bioorchestra, Brainstorm Therapeutics, Celgene, EIP Pharma, Eisai, Grifols, Novo Nordisk, PeopleBio, Roche, Toyama, Vivoryon. She serves on editorial boards of Medidact Neurologie/Springer, Alzheimer Research and Therapy, Neurology: Neuroimmunology & Neuroinflammation, and is editor of a Neuromethods book Springer. She had speaker contracts for Roche, Grifols, Novo Nordisk.